StockData
Synlogic, Inc. logo

Synlogic, Inc. (SYBX) company profile

SYBXOTCPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 6/30
$1.07+0.07 (+7.00%)

Close on Oct 19, 2026Market cap $13.29MP/E –Yield –

About Synlogic

Pharmaceutical Preparations, SIC 2834

Synlogic, Inc. is a biopharmaceutical company that formerly developed novel therapeutics using synthetic biology to treat serious illnesses, specifically rare metabolic diseases. The company’s pipeline centered on genetically engineered bacterial therapeutics, known as Synthetic Biotics, designed to target conditions such as phenylketonuria, homocystinuria, hyperoxaluria, hyperuricemia, and hyperammonemia, along with inflammatory and autoimmune disorders. Following the discontinuation of its lead clinical study, Synlogic operates as a public shell company whose primary activities involve reviewing strategic alternatives, which include potential mergers or an outright sale of the business.

The company operates with a single full-time employee and maintains no ongoing clinical trials or active research and development programs. Its intellectual property portfolio includes over 114 company-owned patents and patent applications across the United States and international jurisdictions, covering bacterial chassis, genetic circuitry, and specialized manufacturing processes. Synlogic maintains its principal executive offices in Winchester, Massachusetts.

Summary of the business section of Synlogic's latest annual report, written by StockData.

Company profile

Company

Legal name
Synlogic, Inc.
Founded
2007
Headquarters
Winchester, MA
Address
Po Box 30 01890
Phone
(617) 659-2802
Employees
1, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
KPMG LLP, Boston, MA

Stock & identifiers

Ticker
SYBX
Exchange
OTC
IPO date
Oct 1, 2015
Shares outstanding
12M, Aug 4, 2026
Public float
$4.40M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-15 reverse, Nov 9, 2023; 1-for-7 reverse, Aug 28, 2017; 1-for-7.25 reverse, Aug 25, 2017
SEC CIK
1527599
CUSIP
87166L209
ISIN
US87166L2097
FIGI
BBG000R33JD4
Share class FIGI
BBG001T92245
LEI
5493007C6UCNXL4HOI66
EIN
26-1824804

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Mary Beth DooleySee Remarks below12,744
Mohamad MakhzoumiDirector–
Scott D. SandellDirector7,151,713
Anthony A. Florence Jr.Director4,228,940
New Enterprise Associates 14, L.P.Director2,114,375
NEA Partners 14, L.P.Director–
Nea 14 Gp, LtdDirector4,228,940
James P. FlynnDirector15,000
Richard P. SheaDirector15,506

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2024
Dr Aoife Brennan
$1.12M$807.47K$486.49K$4–
FY2024
Mr Antoine Awad
$1.26M$1.13M$486.49K$4–
FY2023$1.22M$808.64K$666.60K$11–
FY2022$1.68M$659.01K$876.85K$31–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2024

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsIncentive payOtherTotalvs. prior year
Mary Beth Dooley
Principal Executive Officer and Principal Financial Officer (5)
$325.00K$53.64K$97.50K$10.35K$486.49K+12%
Antoine Awad
Former Principal Executive Officer (6)
$437.71K$130.75K–$689.86K$1.26M+79%
Aoife M. Brennan
Former President and Chief Executive Officer (7)
$119.22K$290.55K–$710.66K$1.12M-8%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Oct 1, 2015
Offer price
$7.00
Securities offered
6,250,000
Gross proceeds
$43.75M
Exchange
Nasdaq
First trading day
Sep 30, 2015
Lock-up ends (est.)
Mar 28, 2016

“Our common stock has been approved for listing on The NASDAQ Global Market under the symbol "MIRN." We expect that the initial public offering price will be $7.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of March 5, 2026, we had one full-time employee, primarily engaged in the assessment of strategic transactions, as directed by the Company's board of directors.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?